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Abstract
Graves’ disease is an autoimmune disorder in which hyperthyroidism (over 
active thyroid) is caused by the autoantibodies against the TSH receptor. It is mainly 
characterized by the appearance of goiter. The symptoms are wide ranging as 
thyroid hormone affects many body systems. It is common in women and in people 
with age below than 40. Graves’ disease is caused by a combination of genetic and 
environmental factors while genetics being the main cause. Graves’ disease is not 
a single gene defect but has a complex pattern of inheritance. Today it is clear that 
genetic predisposition to Graves’ disease is caused by multiple genes. HLA gene is 
one the most studied gene predisposing to Graves’ disease. Lot of polymorphisms 
in this gene has been to be associated with the disease. Lymphoid tyrosine phos-
phatase encoded by the gene PTPN22 has been found to increase the risk of many 
autoimmune diseases including Graves’ disease. The best documented association 
of PTPN22 variants to autoimmune disorders including GD is rs2476601 (C1858T). 
Other genes associated with the risk of GD are thyrotropin receptor (TSHR), thyro-
globulin gene, FCRL3, SCGB3A2, and CTLA4. This chapter will discuss in detail the 
genetics, pathophysiology, diagnosis and treatment of Graves’ hyperthyroidism.
Keywords: graves’ disease, GD, HLA region, PTPN22, CD40, CTLA4, CD152, TSHR, 
Tg, FCRL3, SCGB3A2
1. Introduction
Graves’ Disease (GD) was named after Robert J. Graves, who first recognized 
this disease in the 19th century as a syndrome with enlarged and overactive thyroid 
gland (hyperthyroidism due to circulating autoantibodies), an high heart rate, and 
eye abnormalities (Figure 1). On the quality of life, GD has unpropitious effects 
[1], as a consequence of somatic and psychiatric symptoms, an inability to work 
and is connected with an increased risk of death [2]. The autoimmune basis of the 
GD results from complex interactions between different factors which include 
genetic, endogenous and environmental factors, and this is compulsory for current 
understanding of this disease [3, 4]. The circulating antibodies (IgG) that binds 
and activates the G-protein–coupled thyrotropin receptor leads to hyperthyroidism 
in this disease [5]. In this disease the G-protein–coupled thyrotropin receptor after 
getting activated stimulates follicular cell growth and excessive development which 
results in the enlargement of thyroid gland and also increase in thyroid hormone 
production and the fraction of triiodothyronine (T3) relative to thyroxine (T4) in 
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thyroid secretion [6]. In GD the suppressed serum thyrotropin level and elevated 
levels of serum T4 and T3 are revealed by the thyroid functioning tests. A term 
known as subclinical hyperthyroidism is referred when serum thyrotropin level is low 
as compared to normal serum levels of T4 and T3 [7].
2. Epidemiology
GD with an annual incidence of 20 to 50 cases per 100,000 persons is the most 
common cause of hyperthyroidism [8]. The incidence of GD peaks between 30 to 
50 years of age, but people can be affected at any age. The lifetime risk for women 
is 3% and for men it is 0.5%. The risk of GD is not influenced by Long-term varia-
tions in iodine intake, but rapid repletion can transiently increase the incidence. 
The GD–associated incidence of ophthalmopathy is 16 cases per 100,000 in women 
and in men it is 3 cases per 100,000 annually. It is more common in whites than in 
Asians [9]. Older men develop severe ophthalmopathy more likely than younger 
persons [10]. Subtle abnormalities are revealed in 70% of patients by orbital imag-
ing with GD [11]. In up to 50% of patients in specialized centres, clinically con-
sequential ophthalmopathy is detected with GD, and as a consequence of corneal 
breakdown or optic neuropathy in 3 to 5% of such patients, sight is threatned [12]. 
The thyroid levels remain normal or autoimmune hypothyroidism develops either 
in 10% of the persons with ophthalmopathy [10–12]. In the Whickham study a 
population-based survey in England, the annual incidence of Graves’ disease was 
approximately 80 per 100,000 women, with most other surveys reporting inci-
dence rates ranging from 15 to 50 per 100,000 persons per year while as the annual 
incidence in English men was approximately eight to ten fold lower than women 
(10 per 100,000) in keeping with gender differences seen in other thyroid diseases 
[13]. The incidence of Graves’ hyperthyroidism in area of particularly high iodine 
intake (Japan), has been reported to be as high as 200 cases per 100,000 general 
population [14]. Similarly, following the introduction of iodine supplementation, 
an increases in the apparent incidence of GD have been reported, although in an 
area of mild to moderate iodine deficiency (Switzerland), a 33% reduction in the 
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3. Pathophysiology of Graves’ disease
In GD, four standard thyroid antigens: thyroglobulin, thyroid peroxidase, 
sodium-iodide symporter and the thyrotropin receptor are recognized to direct B 
and T lymphocyte-mediated autoimmunity. However, the primary auto antigen 
of GD is the thyrotropin receptor itself and is responsible for the manifestation of 
hyperthyroidism. In this disease, the antibody and cell-mediated thyroid antigen-
specific immune responses are properly defined. The development of hyperthy-
roidism in healthy subjects by transferring thyrotropin receptor antibodies in 
serum from patients with GD and the passive transfer of thyrotropin receptor 
antibodies to the foetus in pregnant women are the direct proof of an autoimmune 
disorder that is mediated by means of autoantibodies. By circulating autoantibod-
ies against the thyrotropin receptor, the thyroid gland is under continuous stimu-
lation, and because of the increased production of thyroid hormones pituitary 
thyrotropin secretion is suppressed [16]. In the immunoglobulin G1 subclass, 
the stimulating activity of thyrotropin receptor antibodies is found mostly. The 
release of thyroid hormone and thyroglobulin that is mediated via 3,'5′-cyclic 
adenosine monophosphate (cyclic AMP) are caused by these thyroid-stimulating 
antibodies, and they also stimulate iodine uptake, protein synthesis, and thyroid 
gland growth. In the etiology of hyperthyroidism in GD the anti-thyroglobulin, 
anti-sodium-iodide symporter, and anti-thyroid peroxidase antibodies seem to 
have a very little role. However, against the thyroid, these are markers of auto-
immune disease. In persons with autoimmune thyroid disease, intrathyroidal 
lymphocytic infiltration is the initial histologic abnormality which has a direct 
correlation with thyroid antibodies’ titer [17, 18]. In addition to autoantigens, 
the cells of thyroid produce specific immune mediators such as cytokines and 
Fas which are involved in various immune process including complement leg-
islation and T cell adhesion. Those individuals who are suffering from Graves’ 
disease have lesser percentage of CD4 lymphocytes in thyroid as compared to 
their peripheral blood. In addition, the CD4 reduction in these patients may also 
be related to the elevated Fas expression in intrathyroidal CD4 T lymphocytes. 
CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 are several autoimmune 
thyroid disease susceptibility genes that have been identified. Either to GD or 
Hashimoto thyroiditis, some of these susceptibility genes are unique, while others 
confer susceptibility to both conditions. With environmental factors or activities 
to precipitate the onset of GD the genetic predisposition to thyroid autoimmunity 
might also interact [17–19]. The RNASET2-FGFR1OP-CCR6 region at 6q27 and an 
intergenic region at 4p14 are two new susceptibility loci that had been found [20]. 
Moreover, thyroid-stimulating hormone receptor and major histocompatibility 
complex class II versions have strong associations with thyroid stimulating hor-
mone receptor autoantibodies (TRAb)-positive GD [21]. Compared with healthy 
controls, GD patients have higher rate of peripheral blood mononuclear cell 
conversion into CD34+ fibrocytes. The production of inflammatory cytokines like 
Inter-leukin 6 (IL-6) and TNF-alpha by these cells after piling up in orbital tissues 
also contribute to the pathophysiology of thyroid eye disease (opthalmopathy) 
[22]. In a whole genome association study of more than 1500 individuals suffering 
from Graves’ disease and equal controls, six susceptible loci which are (CTLA4; 
cytotoxic T-lymphocyte-associated protein 4, MHC; major histocompatibility com-
plex, FCRl3; Fc receptor-like protein 3, TSHR; thyroid stimulating hormone receptor, 
RNASET2-FGFR1OP-CCR6 region at 6q27, and an intergenic region at 4p14) have 
been discovered to be associated with GD. Figure 2 describes the pathophysiology 
of Graves’ Disease [23].
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4. Genetics of Graves’ disease
GD is a complex autoimmune disorder which affects the functioning of the 
thyroid gland, which is the butterfly shaped gland in the lower neck. Specific 
antibodies targetting the thyrotropin receptor are found in about 95% of patients 
with GD. GD is thought to result from a combination of environmental and genetic 
factors most of which are unknown. A number of genes predispose to the GD 
which include HLA region, protein tyrosine phosphatase-22 (PTPN22), cluster of 
differentiation 40(CD40), the cytototoxic T lymphocyte- Associated factor4 (CTLA4 or 
CD152), thyrotropin receptor (TSHR), thyroglobulin (Tg), FCRL3 (FC receptor-like-3), 
Secretoglobulin 3A2 (SCGB3A2) gene encoding secretory uteroglobin- related protein 
1 (UGRP) and many others. The role of these genes in the pathophysiology of GD is 
discussed below:
4.1 HLA region
Human leukocyte antigen (HLA) region (6p21) within the human genome codes 
for 252 expressed loci including numerous key immune response genes is the most 
gene dense region [24]. This region contains the highest degree of polymorphism 
within the genome and is divided into different classes which includes the extended 
class I, classical class I, classical class III, classical class II and extended class II [24] 
(Figure 3). The densest linkage disequilibrium (LD) is also shown by this gene, 
extending up to 540 kb [25], which compares with distances of between 1 and 
173 kb seen in the rest of the genome [26]. When trying to tease out the exact site of 
etiological variants, the degree of LD within the region is challenging. Most studies 
highlights the importance on the role of HLA class II encoded HLA-DR and –DQ 
molecules, which present exogenous antigens for recognition by CD4+ T helper 
(Th) cells. Including GD, strong associations of HLA with almost all autoimmune 
disorders have been detected. Many studies regarding association of HLA alleles 
with GD have been done. Among different ethnic populations, association of HLA 
alleles with GD varies like HLA-B*08, DR3 and DQA1*05:01 are associated with a 
Figure 2. 
Pathophysiology of Graves’ disease.
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high risk of GD, and HLA-DRB1*07:01 is a protective allele against GD in Caucasian 
populations [27]. HLA alleles have been shown to predispose certain groups of 
people to the disease and vary regionally. British Caucasians showed role of HLA 
class II alleles DRB1-0304, DQB1-02, and DQA1-0501 [28]. The HLA complex 
shows strong linkage disequilibrium. In Caucasians populations, It is found that 
there is strong linkage disequilibrium between the genes that codes DR and DQ 
molecules therefore the existence of a particular DRB1 variant to a larger degree 
determines DQA1 and DQB1 alleles. DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR17, 
DQ2) and DRB1*04:01- DQA1*03:01-DQB1*03:02 (DR4, DQ8) are HLA haplotype 
combinations in GD sibling pairs. The maximum risk related to this disease is asso-
ciated with DR17, DQ2 while as the HLA-DRB1*07 (DR7) is protective for Graves’ 
disease. The recessive inheritance of MHC related susceptibility is favored by the 
distribution of HLA-B8 genotypes and it is in close accord with Hardy–Weinberg 
equilibrium proportions. The possibility that an individual will be affected with GD 
depends on sex, HLA genotype, and family history. 14.9% of DR3-positive women 
with an affected first-degree relative are liable to be affected [29]. HLA Class I 
is also linked with GD, the disease may be mainly associated with alleles of HLA 
class I, in particular HLA-C*07 whereas C*03 and C*16 provides protection [30]. 
HLA-DPB1*05:01 was the main gene predisposing to GD. Other alleles included 
B*46:01, DRB1* 15:02 and 16:02 whereas DRB1*12:02 and DQB1*03:02 provide 
protection. The association of DQA1*05:01 with GD was not supported by Linkage 
Disequilibrium patterns observed in Asians [31]. Peptides derived from TSHR are 
the cause of association with HLA and development of immune response. Other 
cause is owing to thymic selection affecting positive and negative selection of T cell 
clones with regulatory or effector functions. Moreover, impact on NK cell reper-
toire through interactions with killer immunoglobulin-like receptors (KIR) and/or 
serving directly as a source of auto antigens after misfolding and presentation by 
HLA class II molecules [30]. Development of Graves’ disease is related to HLA-DR3. 
The extracellular domain (ECD) of human TSH receptor (hTSH-R) is a crucial 
antigen in Graves’ disease. hTSH-R peptide 37 (amino acids 78-94) is an important 
immunogenic peptide [32]. HLA is the cause of many diseases, the disease occurred 
at an earliest age in HLA-DR3 positive patients and important link between exoph-
thalmos and either exophthalmos and/or soft tissue modifications were found with 
DR3. HLA-DR3 positive patients were found to be more resilient to radioiodine 
therapy than patients negative for these antigens [33]. It has been hypothesized that 
arginine at position 74 of the HLA- DRB1 chain has role in GD pathogenesis. But 
the most common residues at position 74 of DRB1*15:01 and DRB1*16:02 reported 
in our association study are both alanine and it is considered to be neutral for GD 
risk [34]. On the other hand, HLA region is linked to GD susceptibility in both 
Figure 3. 
HLA region on chromosome 6p21. a) nucleotide length of genes of HLA, b) regions of HLA genes.
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Caucasian and Chinese Han populations [35]. The associated alleles vary from those 
in Causacians. HLA-DPB1*05:01 is the major gene of GD in our population, B*46:01, 
DQB1*03:02, DRB1*15:01 and DRB1*16:02 were closely linked with GD [31]. As per 
the other meta-analysis study, the HLA-B*46 allele is a risk factor for GD in Asian 
populations. The distribution of HLA-B*46 and HLA-B*08 vary between European 
and Asian populations. The allelic frequency of HLA-B*08 is around 12%, while the 
allelic frequency is 0.3 to 0.5% in most Asian populations. By contrast, the allelic 
frequency of HLA-B*46 is 3.9 to 8.6% in Asian populations and almost zero in 
Europe populations [35]. Figure 4 depicts the classical HLA Class I and II pathways.
4.2 Protein tyrosine phosphatase-22 (PTPN22)
Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) is also known as 
PTPN22. This in humans is encoded by the PTPN22 gene [36]. This gene has various 
variants. The mutations of this gene are associated with increase or decrease in the 
risk of autoimmune diseases. In many autoimmune diseases, this gene has been 
found strongly associated after HLA [37]. rs2476601 (C1858T) is the best known 
association of PTPN22 variants to autoimmune condition including GD. This SNP 
(R620W) located in the P1 proline - rich motif of PTPN22 binds with strong affin-
ity to the SH3 domain of tyrosine kinase, Csk. This mutation disrupts the interac-
tion between PTPN22 and Csk [38] and also increases phosphatase activity which 
inturn suppresses the TCR signaling more efficiently than the wild type [39]. A role 
of PTPN22 in T-cell regulation has been found by the results of knocking out the 
murine homolog of PTPN22, which lowered thresholds for T-cell-receptor signal-
ing and inhibited production of IL-2 in these animals [40]. This PTPN22 620 W 
substitution, a gain of function mutation resulting in the reduction of phosphoryla-
tion of key signaling molecules and associated downregulation of TCR signaling 
which inturn leads to the inhibition of expansion of T cells, weakening of the 
positive selection in the thymus, and decreasing the antibodies’ titer by reducing 
the activity of helper T lymphocytes [41]. Association between the GD and PTPN22 
620 W polymorphism has been demonstrated in several studies among Caucasians 
Figure 4. 
Classical HLA class I and II pathways.
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with odds ratio as OR 1.5-1.9 [42], which makes PTPN22 620 W polymorph one of 
the strongest known genetic factors influencing to autoimmune diseases. In polish 
population a gene dose-dependent effect of PTPN22 ‘T’ allele on the age of onset 
of GD has been found [42] but that was not replicated in a cohort study done in UK 
[43]. The other available results have shown that the PTPN22 locus contains other 
functionally important variants, particularly those conferring protection.
4.3 Cluster of differentiation 40 (CD40)
The Cluster of Differentiation (CD) are cell surface proteins with each of them 
assigned a specific number thereby allowing cell phenotypes to be recognized. 
Surface expression of a particular CD molecule is functional for the characterization 
of cell phenotypes. These molecules can act either as receptors or ligands. Some 
CD proteins though do not play role in cell signaling, but do have other functions, 
such as cell adhesion. CD for humans is numbered upto 371 with their specific 
functions. CD40 is a costimulatory protein found on the antigen- presenting cells 
and results in their activation. The binding of CD154 (CD40L) on helper T cells 
to CD40 activates antigen presenting cells and induces a variety of downstream 
effects. Deficiency can lead to Hyper-IgM syndrome type3. It is located on chromo-
some 20 in humans and chromosome 2 in mouse. Disruption of the CD40- CD40L 
co-stimulatory pathway has been found in many autoimmune diseases, including 
GD. on the basis of a genome-wide linkage study in GD, CD40 has been associated 
with GD as a positional candidate which implicated 20q11 chromosomal region, 
designated GD-2, as harboring a susceptibility locus [44]. C/T polymorphism 
(rs1883832) located at position −1 relative to translation start site affects the initia-
tion step of translation as it has a direct effect on kozak sequence. The C allele of 
rs1883832 has been found to confer risk of GD among Caucasians whereas the results 
from in vitro transcription/translation system suggested that this allele predisposes 
to GD by increasing the efficiency of translation of CD40 mRNA [44]. There is a 
close association between GD and C variant of rs1883832 as supported by studies in 
the Japanese population although in this population the effect may be constrained 
to patients with the late onset of disease [45] and/or to the CC and CT genotypes, 
signifying a dominant rather than a recessive model of inheritance [45]. Recently, 
siRNA mediated inhibition of CD40 expression was evaluated for potential to 
prevent development of GD in mice immunized with adenovirus expressing human 
TSHR A subunit. In spite of successful lowering of CD40 expression, no effect on 
the rate of disease induction was observed [46].
4.4 The cytotoxic T lymphocyte-associated factor 4 (CTLA4 Or CD152)
It is a protein receptor that functions as an immune checkpoint and down-
regulates immune responses. It is constitutively expressed in regulatory T cells but 
only upregulated in conventional T cells after activation; a phenomenon which is 
particularly notable in cancers [47]. It is homologous to the T-cell co-stimulatory 
protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and 
B7-2 respectively, on antigen-presenting cells. CTL4-4 binds CD80 and CD86 
with greater affinity and avidity than CD28 thus enabling it to outcompete CD28 
for its ligands. CTLA4 transfers an inhibitory signal to T cells, [48] whereas CD28 
transmits a stimulatory signal [48]. CTLA4 is also found in regulatory T cells and 
thereby contributing to their inhibitory function. CTLA4 consists of four exons 
encoding different functional domains such as a leader sequence and extracel-
lular, transmembrane as well as cytoplasmic domains. The most reliable associa-
tions with GD within CTLA4 locus were found with three polymorphisms: the 
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AT-microsatellite polymorphism (ATn) at the 3’untranslated region (3’UTR) of the 
gene [49]. It has been proposed that this AT-repeat allele decreased the` stability 
of CTLA4 mRNA thus dampening the inhibitory function of the protein and thus 
diminishing the control of T-cell proliferation [50]. The second polymorphism 
implicated was rs231775 (A49G) in the signal peptide causing a substitution of Thr 
to Ala [51]. This amino acid change could influence post-translational processing 
leading to inefficient glycosylation of the autoimmunity predisposing variant [52]. 
Another widely studied genetic polymorphism in CTLA4 gene is rs3087243 (CT60) 
located downstream from the 3’UTR of the CTLA4 [53]. After taking into account 
the CT60 genotype, Examination of full-length (flCTLA-4) and sCTLA-4 expres-
sion revealed a lower expression of sCTLA-4 in persons homozygous for the G allele 
[54]. But, in a larger Swedish study this result was not replicated which also did not 
find any association between concentration of serum sCTLA4 and disease status 
or CT60 genotype [54]. Lately, in Japanese patients a noteworthy association with 
CTLA4 CT60 was found for GD with OR=2.97. The present state of knowledge does 
not specify evidently the mechanism behind the association of CTLA4 with GD. 
However, CTLA4 polymorphism is consistently associated with thyroid autoim-
mune diseases in the majority of populations.
4.5 The thyrotropin receptor (TSHR)
The thyrotropin receptor (TSHR) responding to thyrotropin (thyroid-
stimulating hormone, TSH) is a Gs-protein coupled receptor and stimulates the 
production of thyroxin (T4) and triiodothyronine (T3). It is primarily found on 
the surface of the thyroid epithelial cells [55], but also found on adipose tissue and 
fibroblasts. A G protein signal cascade is activated upon the binding of circulating 
ligand TSH which activates adenylyl cyclase that synthesizes cAMP from ATP and 
subsequently resulting in increased intracellular levels of cAMP. cAMP functions 
as a secondary messenger and activates all functional aspects of the thyroid cells 
which include thyroglobulin synthesis, iodine pumping, endocytosis, iodination, 
proteolysis, thyroid peroxidase activity and hormone release. TSHR gene is located 
on 14q31 [56] and consists of 13 exons [57]. The TSHR is among the susceptibility 
genes of GD because it encodes for a protein that is both responsible for the clinical 
manifestations of the disease and is the direct target of the autoimmune response 
in GD. The anti-TSHR antibodies in serum are the main serological manifestations 
of GD. Indeed, TSHR- stimulating antibodies (TSAbs) are present in nearly all 
cases of GD and severity of the disease correlates with TSAbs levels. One of the 
first non-MHC genes to be tested for association with the disease was TSHR. Three 
germline missence mutations (a substitution of aspartic acid (D) for histidine 
(H) in position 36 (D36H); a substitution of a proline (P) for threonine (T) in 
position 52(P52T), and a substitution of aspartic acid (D) for glutamic acid (E) in 
position 727 (D727E) were primarily described in individuals suffering from GD 
and proposed to be associated with the disease [3]. Of these three, D36H and P52T 
are the two mutations which are located in the putative ligand binding region of 
the extracellular domain of the TSHR, while the third one, D727E lies within the 
intracellular domain of the receptor.
4.6 FCRL3 (FC receptor-like-3)
Fc receptor-like protein 3 is a protein that in humans is encoded by FCRL3 gene 
[58]. It is located on 1q23.1. This gene located on q arm of chromosome 1st is one 
of the several Fc receptors like glycoproteins which encode a member of the IR 
superfamily. The encoded protein plays a role in regulation of the immune system 
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and in its cytoplasmic domain it contains immunoreceptor-tyrosine activation 
motifs and immunoreceptor-tyrosine inhibitory motifs. Rheumatoid arthritis, 
autoimmune thyroid disease, and systemic lupus erythematosus have been associ-
ated in the mutation of this gene [58]. FCRL3 is a novel immunoregulatory gene 
believed to perform similar functions as FC gamma receptors due to high structural 
homology between them. FCRL3 gene polymorphism is related to the susceptibil-
ity to GD with regional and ethnic variability [59]. A SNP at the position -169A/G 
(rs7528684) in promoter of FCRL3 gene has been found to be associated with GD. 
Correlation of this SNP to serum levels of FT3, FT4, TSH and TRAb, gender, age, 
TpoAb, TgAb, severity of goiter and presence or absence of exophthalmos in GD 
have been widely investigated [59]. There is an association of anther SNP rs3761959 
(tagging rs7528684) with GD. Overall the available data suggest that genetic 
polymorphism(s) modifying susceptibility for GD do exist in the FCRL3 region but 
the primarily associated variant(s) remain(s) to be found [60].
4.7 Secretoglobin 3A2 (SCGB3A2) gene
This gene is present on chromosome 5 in humans and chromosome 18 in mouse. 
It is a homodimeric protein thought to play a role in the modulation of inflam-
mation and tumorigenesis. SCGB3A2 is a member of secretoglobin superfamily, 
a family of small, secreted proteins found in animals exclusively of mammalian 
lineage. SCGB3A2 mRNA is predominantly expressed in the lung with low levels of 
expression in the thyroid. Variants in the promoter of the SCGB3A2 gene encoding 
secretory uteroglobin-related protein 1 (UGRP1) have been found associated with 
GD in an extensive study of a total of ~2500 patients and controls from the Chinese 
population who aimed to explain signals in the chromosomal region 5q12-q33 
obtained in previous studies using linkage analysis [61–63]. Song et al. reported the 
strongest association of GD with rs1368408 (112G/A, OR=1.28, P=1.43x10-6) and 
SNP75 (−623~−622 AG/−T, OR=1.32, P=7.62x10-5) [60, 61]. Association between 
GD and the A allele of rs1368408 (OR=1.18, P=0.007) was independently confirmed 
in a similarly sized UK cohort [64]. Recently, further evidence for association 
between rs1368408 and GD was provided by a study in a Russian cohort (~1500 
cases and controls, OR=1.33, P=2.910-5) [60]. It should be noted that a relatively 
early study in a Chinese population did not observe the effect of rs1368408, 
although this might have been caused by low power due to limited numbers of 
subjects (~200 cases and controls) [62]. Till present it is still not clear how variants 
in SCGB3A2 predispose to GD.
There are other genes which have strong association with GD such as cytokine 
genes: IL3, IL4, IL5, IL9, IL13 and the ADRB2 gene encoding beta-2-Adrenergic 
receptor [65–67] were all associated with GD.
5. Diagnosis of Graves’ disease
The diagnosis to confirm the cause of Graves’ hyperthyroidism is based on the 
clinical and biochemical manifestations of hyperthyroidism and on the clinical 
and laboratory features. For the presence of hyperthyroidism, measurement of 
serum thyrotropin is a useful screening test, because the secretion of thyrotropin 
is reduced by very small increase in thyroid secretion, so by the measurement of 
serum free thyroxine the diagnosis of hyperthyroidism must be confirmed [68]. 
Patients may have only increased secretion of triiodothyronine in the earliest 
stage of Graves’ hyperthyroidism; therefore, patients with normal serum free 
thyroxine concentrations and low serum thyrotropin concentrations, serum free 
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triiodothyronine should be measured. Because of the use of certain drugs and 
increase in thyroid hormone–binding proteins, measurements of serum total 
thyroxine and triiodothyronine are less reliable as it can cause high values [69]. In 
patients with hyperthyroidism and a diffuse goiter, the signs of ophthalmopathy or 
dermopathy are sufficient to confirm the diagnosis of GD. In patients with GD, other 
autoimmune disorders occur more frequently (Type 1 diabetes mellitus, Addison’s 
disease, Vitiligo, Pernicious anemia Alopecia areata, Myasthenia gravis, Celiac dis-
ease) and their presence therefore supports this diagnosis. Occasionally, in patients 
with pre-existing nodular goiter, GD occurs which causes confusion. The presence 
of a high serum concentration of thyroid peroxidase antibody which is present in 
about 75 percent of patients with Graves’ hyperthyroidism, or a thyroid radionuclide 
scan demonstrating a diffuse goiter provides evidence of GD, when the diagnosis 
is unclear clinically. Occasionally, to distinguish between Graves’ hyperthyroid-
ism and thyrotoxicosis caused by painless, destructive (autoimmune) thyroiditis, 
thyroid radionuclide studies may be indicated especially in women post-partum. 
Patients may have a small diffuse goiter with painless thyroiditis, like those with GD. 
However, it is very unlikely that thyrotoxicosis due to painless thyroiditis will last 
longer than two months [70].
5.1 Measurement of thyrotropin-receptor antibodies in serum
It is largely a matter of individual preference, whether serum thyrotropin-
receptor antibodies should be measured in the differential diagnosis of GD, 
some argue that a test for the antibodies should be done routinely, and others 
that a diagnosis of GD can nearly always be inferred correctly on the basis of the 
clinical findings. The immunoglobulin-mediated inhibition of the binding of 
radiolabeled thyrotropin to thyrotropin receptors is most widely used assay for 
thyrotropin-receptor antibodies and is positive approximately in 80% of indi-
viduals suffering for Graves’ hyperthyroidism [2]. Up to 99% sensitivity is shown 
by newer assays. Even though a positive result might specify the occurrence of 
either thyroid- stimulating antibodies or thyrotropin-receptor– blocking antibod-
ies, it is rational to conclude that a positive test in the individual suffering from 
hyperthyroidism is owing to thyrotropin-receptor–stimulating antibodies. With 
time as the mechanism of the interactions of antibodies with the thyrotropin 
receptor improves, it would be possible to develop simple, precise immunoassays 
for thyroid-stimulating antibodies for routine use. The antibodies identified by 
bioassays that measure the synthesis of cAMP in retort to the stimulation of thy-
rotropin receptors are only thyroid-stimulating antibodies — for instance, in cells 
transfected with thyrotropin receptor— but such assays are relatively expensive 
and not widely available [71].
5.2 Computed tomography (CT) or magnetic resonance imaging (MRI)
CT and/or MRI of the orbits is indicated if there is any uncertainty about the 
cause of ophthalmopathy, particularly in a patient with unilateral exophthalmos, 
to rule out a retrobulbar tumor or arteriovenous malformation. Approaches used 
in assessing the activity of ophthalmopathy are very helpful in determining which 
individuals will be benefitted from immunosuppressive treatment. Measurement of 
the relaxation time for extraocular muscles on T2-weighted MRI, Clinical activity 
scores (CAS), and orbital scanning with indium In 111 pentetreotide [54] have all 
been suggested for this purpose but have not been fully assessed. These above tests 
are not needed for the majority of individuals, who have only mild or moderate 
Graves’ ophthalmopathy [72].
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6. Therapy for Graves’ disease
According to age, severity of hyperthyroidism, goiter size, presence and degree 
of ophthalmopathy, as well as patient’s personal preference, GD treatment should 
be tailored in each individual patient. Medical treatment with anti-thyroid medi-
cine (thionamides) is usually suggested in all patients to revive euthyroidism at 
first. Once euthyroidism is achieved, the long strategy comprises many choices, 
including relatively long-term (usually twelve to twenty four months) course of 
anti-thyroid drugs, radioactive iodine or surgery. Beta-blockers, if not inadvis-
able are time and again used prior to restoration of euthyroidism to reduce the 
symptoms of thyrotoxicosis. The thyroid hormone formation is blocked by specific 
thionamides or antithyroid drugs (propylthiouracil and methimazole). These drugs 
prevent the thyroid hormone production by inhibiting iodine organification and 
coupling of iodotyrosines. Treatment of this disease with these drugs is usually 
well tolerated. Some of the side effects like skin rash and, hardly Granulopenia, 
Hepatits and Arteritis may occur. Methimazole is currently most well liked over 
propylthiouracil, owing to the proof of a lower prevalence of severe side-effects, 
particularly hepatitis [73], with the exception of the first trimester of pregnancy, 
when propylthiouracil is preferred due to the increased rate of congenitalmal 
formations, especially aplasia cutis, which has been reported with the utilization 
of methimazole [74]. Due to the high probability of recurrence of hyperthyroidism 
after the withdrawal of therapy, this method is not suggested to individuals having 
large goiters. Contrary, in individuals with thyroid eye disease (ophthalmopathy), 
we tend to like a surgical removal of all or part of the thyroid gland (thyroid-
ectomy), radioiodine ablation, or both owing to the pathogenetic role of cross-
reactive antigens between the thyroid and orbital tissues [75]. In some centers, 
the methimazole is used at higher doses than desirable amounts needed to correct 
hyperthyroidism in coalition with thyroid hormone for block and replacement 
treatment. This tactic relies on plausible immunosuppressive methimazole action, 
which still has not been incontestable in studies related to humans [76]. Radioiodine 
is ideally administered after the accomplishment of euthyroidism with the help of 
anti-thyroid drugs. Hypothyroidism is induced to attain a stable remission of GD, 
this is the goal of the treatment. To calculate the appropriate radioactive iodine dose 
to be given, 24 hour radioactive iodine uptake is usually performed before treatment 
and used together with gland volume. However, a fixed radioiodine dose may also 
be given without interfering with the outcome [77]. Radioiodine treatment, when 
using appropriate dose, within 1 to 6 months in the majority of patients (about 
80%), it leads to hypothyroidism. Those Patients having large goiter the radioiodine 
therapy should not be used as it has low success rate unless repeated treatments 
are planned. It has been seen that radioiodine has acute side effects which are 
mild, well tolerated and generally self-limiting. Radioactive therapy for the treat-
ment of hyperthyroidism sometimes causes a transitory pain and swelling of the 
neck and subsequently requires a treatment with oral glucocorticoids. During this 
process, for a short period of time the symptoms of thyrotoxicosis may exacerbate 
due to the release of preformed thyroid hormones. After radioiodine treatment, 
a transient worsening or more rarely, the fresh appearance of thyroid eye disease 
may occur, but it can be easily prevented by the administration of oral prednisone 
after radioiodine for 8–12 weeks. After radioiodine therapy in adults with Graves, 
there is no evidence of an increased risk of thyroid cancer and other solid tumors as 
well as of leukemia [78]. No major studies are available in children unfortunately. 
So, radioiodine treatment is not recommended before the age of 18–20 years. With 
the exception of a transitory decrease in testosterone levels in men, no effects on 
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with a large goiter has been indicated by Thyroidectomy. The surgical procedures 
most commonly recommended in patients with GD are near total thyroidectomy 
(NT) or total thyroidectomy (TT), consisting in the removal of most or all visible 
thyroid tissue, respectively. Both procedures result in hypothyroidism. Recurrence 
of hyperthyroidism is extremely rare. The rate of post-operative complications (e.g. 
surgical hypoparathyroidism, laryngeal nerve paralysis) is not increased compared 
with that observed using other less aggressive surgical procedures [80]. Briefly, the 
treatment of choice depends on the seriousness and activity of GD. In individuals 
with moderately severe thyroid eye disease, the usage of intravenous glucocorti-
coids is the first-line treatment and if this intravenous glucocorticoids treatment 
fails, orbital decompression is performed [81]. And this rehabilitative surgery 
(orbital decompression, muscle or eyelid surgery) must be considered when the 
eye disease is inactive. No major treatments are required for the majority of patients 
having a mild ophthalmopathy, and patients are given local measurement (e.g. eye 
lubricants, sun glasses) or, based on a recent study, selenium [82].
7. Conclusion
Since the incidence of Graves’ disease is increasing at pace and already told in 
the above chapter that it has an unpropitious effects on the quality of life as it causes 
weight loss, fatigue irritability, goiter (swelling in the thyroid gland) and much 
more. It also affects skin and eyes the conditions called Graves’ dermopathy and 
Graves’ ophthalmopathy respectively. As explained earlier this disease is thought to 
result from a combination of environmental and genetic factors most of which are 
unknown. So it is necessary to understand those factors, which will help us in the 
better management of this disease in future.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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